Dank, MZaluski, JBarone, CValvere, VPeschel, CWenczl, MGoker, ERisse, MLAwad, LBugat, R2019-10-272019-10-2720050732-183X1527-7755https://hdl.handle.net/11454/3735741st Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 13-17, 2005 -- Orlando, FLeninfo:eu-repo/semantics/closedAccessRandomized phase 3 trial of irinotecan (CPT-11)+5FU/folinic acid (FA) vs CDDP+5FU in 1(st)-line advanced gastric cancer patientsConference Object2316308S308SWOS:000230326602054Q1